EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has received a Notice of Allowance from the Israel Patent Office for its ExoPTEN patent, a key component in its regenerative medicine therapy for acute spinal cord injuries. The company is advancing its ExoPTEN nanodrug towards clinical trials and has also partnered with Allele Capital Partners for investor relations services, with plans to increase engagement and potentially uplist to major stock exchanges.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
